Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / April 30, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Compass Therapeutics, Inc. ("Compass" or "the Company") (NASDAQ:CMPX). Investors who purchased Compass securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CMPX.

Compass Investigation Details

On April 27, 2026, Compass issued a press release announcing results from a phase 2/3 study evaluating its drug tovecimig as a biliary tract cancer treatment. Although the press release emphasized that the study "met the key secondary endpoint of [progression-free survival] and showed additional compelling results", the study also missed another key secondary endpoint, overall survival. Following this news, Compass's stock price dropped $3.24 per share, or 64.41%, to close at $1.79 on April 27, 2026.

What's Next for Compass Investors?

If you are aware of any facts relating to this investigation or purchased Compass securities, you can assist this investigation by visiting the firm's site: bgandg.com/CMPX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Compass Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Compass Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC